Residential Rehab

Alcohol withdrawal kindling is the tendency for repeated withdrawal episodes to become progressively more severe, increasing concern for seizures and complicated withdrawal in people with multiple prior withdrawals.

Opioid tolerance means the body becomes less responsive to a given opioid dose over time. After treatment or abstinence, tolerance can fall, making a previously used dose dangerously strong and increasing overdose risk.

Extended-release injectable naltrexone is a monthly opioid-blocking medication approved for opioid use disorder after detoxification and for alcohol use disorder in appropriate patients.

Buprenorphine can be started during addiction treatment when a qualified clinician determines it is appropriate for opioid use disorder. The initiation strategy depends on recent opioid use, withdrawal, fentanyl exposure, and other clinical factors.

Someone may be able to continue buprenorphine or methadone during residential rehab when the medication remains clinically appropriate and the program can coordinate it safely. Medication should not be stopped automatically simply because residential treatment begins.

Medication for opioid use disorder, or MOUD, refers to FDA-approved medications such as methadone, buprenorphine, and naltrexone used to treat opioid use disorder as part of evidence-based care.

Naltrexone and buprenorphine are both FDA-approved medications for opioid use disorder, but naltrexone blocks opioid receptors and requires an opioid-free period, while buprenorphine is a partial opioid agonist that can treat withdrawal and cravings.

Methadone and buprenorphine are both FDA-approved medications for opioid use disorder, but they differ in how they act, where they can be prescribed or dispensed, overdose risk, and how treatment is started.

Low-dose buprenorphine initiation, sometimes called microinduction, starts buprenorphine in very small amounts while a full opioid agonist may still be present, with the goal of reducing precipitated-withdrawal risk.

Buprenorphine induction is the process of starting buprenorphine for opioid use disorder and adjusting it until withdrawal and cravings are controlled without triggering precipitated withdrawal.